Notice of NIDDK Participation in PA-17-098 "Administrative Supplements for Research on Sexual and Gender Minority (SGM) Populations (Admin Supp)"

Notice Number: NOT-DK-17-008

Key Dates
Release Date:  January 11, 2017

Related Announcements
PA-17-098

Issued by
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Purpose

The purpose of this Notice is to inform potential applicants that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is participating, effective immediately, in the following Funding Opportunity Announcement (FOA): PA-17-098 "Administrative Supplements for Research on Sexual and Gender Minority (SGM) Populations (Admin Supp)".

The following sections of the FOA have been changed to reflect NIDDK's participation.

Part I. Overview Information

Components of Participating Organizations
National Cancer Institute (NCI)
National Institute on Aging (NIA)
National Human Genome Research Institute (NHGRI)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute on Deafness and Other Communication Disorders (NIDCD
National Institute of Dental and Craniofacial Research (NIDCR)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute on Drug Abuse (NIDA)
National Institute of Mental Health (NIMH)
National Institute of Nursing Research (NINR)
National Institute on Minority Health and Health Disparities (NIMHD)
National Center for Complementary and Integrative Health (NCCIH)
National Center for Advancing Translational Sciences (NCATS)   
Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP
Division of Program Coordination, Planning and Strategic Initiatives: Sexual & Gender Minority Research Office (SGMRO)
Office of AIDS Research (OAR)
Office of Research on Women’s Health (ORWH)

Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.273; 93.361; 93.350; 93.172; 93.361; 93.213; 93.865; 93.866; 93.399; 93.396; 93.395; 93.394; 93.393; 93.172; 93.307; 93.242; 93.846; 93.847; 93.856; 93.855; 93.279; 93.121; 93.173; 93.313 

Part 2. Section 1. Funding Opportunity Description

IC Specific Considerations

Currently reads:

Applicants are strongly encouraged to discuss their proposed supplement project with the IC Program Official of the parent grant prior to submission of a supplement application in order to ensure that the supplement content area fits with the scientific priorities of the IC and is within the scope of the parent grant; and to ensure that the parent grant mechanism is one the IC will support for a supplement.  In addition to contact with the IC Program Official for the parent grant, applicants are strongly encouraged to include the Scientific/Research Contact listed in Section VII. Agency Contacts in these communications.

Modified to read:
Applicants are strongly encouraged to discuss their proposed supplement project with the IC Program Official of the parent grant prior to submission of a supplement application in order to ensure that the supplement content area fits with the scientific priorities of the IC and is within the scope of the parent grant; and to ensure that the parent grant mechanism is one the IC will support for a supplement. Please note that NIDDK will only consider applications for support which pertain to benign conditions of lower urinary tract or bladder in response to this FOA.  In addition to contact with the IC Program Official for the parent grant, applicants are strongly encouraged to include the Scientific/Research Contact listed in Section VII. Agency Contacts in these communications.

No other changes are being made to this FOA.

Inquiries

Please direct all inquiries to:

Tamara Bavendam, M.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-594-4733
Email: tamara.bavendam@nih.gov